Denali Therapeutics Inc. - Common Stock (NQ:DNLI)

25.67 -1.54 (-5.66%)

Streaming Delayed Price Updated: 3:47 PM EDT, Jul 10, 2026 Add to My Watchlist

Price and Volume

Volume	993,672
Open	27.06
Bid (Size)	25.66 (200)
Ask (Size)	25.68 (300)
Prev. Close	27.21
Today's Range	25.25 - 27.11
52wk Range	12.58 - 27.30
Shares Outstanding	121,640,069
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier

July 09, 2026

From Denali Therapeutics Inc.

Via GlobeNewswire

Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million

June 18, 2026

From Denali Therapeutics Inc.

Via GlobeNewswire

Performance

YTD	+57.8%	+57.8%
1 Month	+23.5%	+23.5%
3 Month	+33.1%	+33.1%
6 Month	+50.4%	+50.4%
1 Year	+71.1%	+71.1%

More News

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease

May 21, 2026

From Denali Therapeutics Inc.

Via GlobeNewswire

Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval ↗

May 18, 2026

Via The Motley Fool

Denali Therapeutics Says AVLAYAH Launch Ahead of Expectations After Hunter Syndrome Approval ↗

May 16, 2026

Via MarketBeat

Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

May 07, 2026

From Denali Therapeutics Inc.

Via GlobeNewswire

Privium Fund Opens $5.07 Million Denali Stake Ahead of FDA Drug Approval ↗

May 05, 2026

Via The Motley Fool

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial Highlighting Biotech’s Shift Toward Science-Driven Asset Valuation

April 20, 2026

Via Investor Brand Network

Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)

April 03, 2026

From Denali Therapeutics Inc.

Via GlobeNewswire

When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech

April 20, 2026

From BioMedWire

Via GlobeNewswire

Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA

April 02, 2026

Via MarketMinute

The Brain Barrier Broken: Inside Denali Therapeutics’ Landmark FDA Approval of AVLAYAH

March 26, 2026

Via Finterra

Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)

March 25, 2026

From Denali Therapeutics Inc.

Via GlobeNewswire

Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

February 26, 2026

From Denali Therapeutics Inc.

Via GlobeNewswire

Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development

February 19, 2026

Via Investor Brand Network

Biogen (BIIB) Q4 Earnings Preview: The "New Biogen" Emerges as Alzheimer's and Rare Disease Pipelines Take Center Stage

February 06, 2026

Via MarketMinute

Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development

February 19, 2026

From BioMedWire

Via GlobeNewswire

Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™

February 05, 2026

From Denali Therapeutics Inc.

Via GlobeNewswire

Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™

February 02, 2026

From Denali Therapeutics Inc.

Via GlobeNewswire

Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™

January 29, 2026

From Denali Therapeutics Inc.

Via GlobeNewswire

Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome

January 06, 2026

From Denali Therapeutics Inc.

Via GlobeNewswire

The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)

December 30, 2025

From Denali Therapeutics Inc.

Via GlobeNewswire

Biggest Stock Movers Today, Dec. 10: PLAB, AVAV, & More ↗

December 10, 2025

Via The Motley Fool

Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

December 10, 2025

From Denali Therapeutics Inc.

Via GlobeNewswire

Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

December 09, 2025

From Denali Therapeutics Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Denali Therapeutics Inc. - Common Stock publicly traded?

Yes, Denali Therapeutics Inc. - Common Stock is publicly traded.

What exchange does Denali Therapeutics Inc. - Common Stock trade on?

Denali Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Denali Therapeutics Inc. - Common Stock?

The ticker symbol for Denali Therapeutics Inc. - Common Stock is DNLI on the Nasdaq Stock Market

What is the current price of Denali Therapeutics Inc. - Common Stock?

The current price of Denali Therapeutics Inc. - Common Stock is 25.67

When was Denali Therapeutics Inc. - Common Stock last traded?

The last trade of Denali Therapeutics Inc. - Common Stock was at 07/10/26 03:47 PM ET

What is the market capitalization of Denali Therapeutics Inc. - Common Stock?

The market capitalization of Denali Therapeutics Inc. - Common Stock is 3.12B

How many shares of Denali Therapeutics Inc. - Common Stock are outstanding?

Denali Therapeutics Inc. - Common Stock has 3B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.